The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences

References

• American Heart Association Heart disease and stroke statistics – 2008 update. 2008www.americanheart.org/downloadable/heart/1200082005246HS_Stats%202008.final.pdf Accessed June 2009.
   Google Scholar
• The Scandinavian Simvastatin Survival Study GroupRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med1998339134913579841303
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial InvestigatorsN Engl J Med1996335100110098801446
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIfor the West of Scotland Coronary Prevention Study Group (WOSCOPS)Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaN Engl J Med1995333130113077566020
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of (AFCAPS/TexCAPS) Air Force/Texas Coronary Atherosclerosis Prevention StudyJAMA1998279161516229613910
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNClearfieldMfor the Air Force/Texas Coronary Atherosclerosis Prevention Study InvestigatorsMeasurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary eventsN Engl J Med20013441959196511430324
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDfor the Treating to New Targets (TNT) InvestigatorsIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005352141425143515755765
   PubMed Web of Science ®Google Scholar
• RidkerPMCannonCPMorrowDfor the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) InvestigatorsC-reactive protein levels and outcomes after statin therapyN Eng J Med20053522028
   PubMed Web of Science ®Google Scholar
• BellostaSFerriNBerniniFPaolettiRCorsiniANon-lipid-related effects of statinsAnn Med20003216417610821323
   PubMed Web of Science ®Google Scholar
• KapurNKRosuvastatin: a highly potent statin for the prevention and management of coronary artery diseaseExpert Rev Cardiovasc Ther2007516117517338662
   PubMedGoogle Scholar
• SchusterHBarterPJStenderSEffective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I)Am Heart J200414770571315077101
   PubMed Web of Science ®Google Scholar
• BallantyneCMBertolamiMHernandez GarciaHRAchieving LDL cholesterol, nonHDL cholesterol and apolipoprotein B target levels in high-risk patient: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY II)Am Heart J2006151975.e1e916644314
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHSteinEASTELLAR Study GroupComparison of the Efficacy and Safety of Rosuvastatin versus Atorvastatin, Simvastatin and Pravastatin Across Doses (STELLAR trial)Am J Cardiol20039215216012860216
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPREVERSAL InvestigatorsEffect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trialJAMA20042911071108014996776
   PubMed Web of Science ®Google Scholar
• De GrootEJukemaJWvan BovenAJEffect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study (REGRESS)Am J Cardiol19957640C46C7793401
   PubMed Web of Science ®Google Scholar
• BlankenhornDHAzenSPKramschDMMARS Research GroupCoronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS)Ann Intern Med19931199699768214993
   PubMed Web of Science ®Google Scholar
• WatersDHigginsonLGladstonePEffects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT)Circulation1994899599688124836
   PubMed Web of Science ®Google Scholar
• CrouseJRIIIRaichlenJSRileyWAMETEOR Study GroupEffect of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trialJAMA20072971344135317384434
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJSipahiIASTEROID InvestigatorsEffect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trialJAMA20062951556156516533939
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNRoseLBuringJECookNRComparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular eventsN Eng J Med200234715571565
   PubMed Web of Science ®Google Scholar
• PaiPKPischonTMaJInflammatory markers and the risk of coronary heart disease in men and womenN Engl J Med20043512599261015602020
   PubMed Web of Science ®Google Scholar
• KoenigWLöwelHBaumertJMeisingerCC-reactive protein modulates risk prediction based on the Framingham risk score: implications for future risk assessment: results from a large cohort study in southern GermanyCirculation20041091349135315023871
   PubMed Web of Science ®Google Scholar
• RidkerPMCookNClinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk ScoresCirculation20041091955195915051634
   PubMed Web of Science ®Google Scholar
• RidkerPMC-reactive protein and prediction of cardiovascular events among those at intermediate riskJ Am Coll Cardiol2007492129213817531663
   PubMed Web of Science ®Google Scholar
• FordESThe metabolic syndrome and C-reactive protein, fibrinogen and leukocyte count: findings from the Third National Health and Nutrition Examination SurveyAtherosclerosis200316835135812801619
   PubMed Web of Science ®Google Scholar
• MokdadAHSerdulaMKDietzWHBowmanBAMarksJSKoplanJPThe continuing epidemic of obesity in the United StatesJAMA20002841650165111015792
   PubMed Web of Science ®Google Scholar
• HeilbronnLKNoakesMCliftonPMEnergy restriction and weight loss on very-low fat diets reduce C-reactive protein concentrations in obese, healthy womenArterioscler Thromb Vasc Biol20012188188311397691
   PubMed Web of Science ®Google Scholar
• KadoglouNPIliadisFAngelopoulouNThe anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitusEur J Cardiovasc Prev Rehabil20071483784318043308
   PubMed Web of Science ®Google Scholar
• PlengeJKHernandezTLWeilKMSimvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reductionCirculation20021061447145212234946
   PubMed Web of Science ®Google Scholar
• RidkerPMfor the JUPITER study groupRosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trialCirculation20031082292229714609996
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAfor the JUPITER study groupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Eng J Med200835921952207
   PubMed Web of Science ®Google Scholar
• GlynnRJDanielsonEFonsecaFAA randomized trial of rosuvastatin in the prevention of venous thromboembolismN Eng J Med200936018511861
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAReduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trialLancet20093731175118219329177
   PubMed Web of Science ®Google Scholar
• FellströmBCJardineAGSchmiederRERosuvastatin and cardiovascular events in patients undergoing hemodialysisN Eng J Med200936013951407
   PubMed Web of Science ®Google Scholar
• BaigentCBurburyKWheelerDPremature cardiovascular disease in chronic renal failureLancet200035614715210963260
   PubMed Web of Science ®Google Scholar
• WannerCKraneVMärzWAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisN Engl J Med200535323824816034009
   PubMed Web of Science ®Google Scholar
• FoleyRNMurrayAMLiSChronic kidney disease and the risk of cardiovascular disease, renal replacement and death in the United States Medicare population, 1998 to 1999J Am Soc Nephrol20051648949515590763
   PubMed Web of Science ®Google Scholar
• GISSI-HF InvestigatorsTavazziLMaggioniAPEffect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized double-blind, placebo-controlled trialLancet20083721231123918757089
   PubMed Web of Science ®Google Scholar
• KjekshusJApetreiEBarriosVfor the CORONA GroupRosuvastatin in older patients with systolic heart failureN Engl J Med20073572248226117984166
   PubMed Web of Science ®Google Scholar
• AmannKMedia calcification and intima calcification are distinct entities in chronic kidney diseaseClin J Am Soc Nephrol200831599160518815240
   PubMed Web of Science ®Google Scholar
• ZoccaliCBenedettoFMallamaciFLeft ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progressionKidney Int2004651492149815086493
   PubMed Web of Science ®Google Scholar
• CowellSJNewbyDEPrescottRJScottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) investigatorsA randomized trial of intensive lipid-lowering therapy in calcific aortic stenosisN Eng J Med200535223892397
   PubMed Web of Science ®Google Scholar
• RossebøABPedersenTRBomanKSEAS InvestigatorsIntensive lipid lowering with simvastatin and ezetimibe in aortic stenosisN Engl J Med20083591343135618765433
   PubMed Web of Science ®Google Scholar
• Antonini-CanterinFHirsuMPopescuBAStage-related effects of statin treatment on the progression of aortic valve sclerosis and stenosisAm J Cardiol200810273874218773999
   PubMed Web of Science ®Google Scholar
• HuskeyJLindenfeldJCookTEffect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S)Atherosclerosis200920520220619124121
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS InvestigatorsEffects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients with Diabetes: An Analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)Am J Kidney Dis2009618 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• NavaneethanSDPansiniFPerkovicVHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisCochrane Database Syst Rev20094152CD00778419370693
   PubMed Web of Science ®Google Scholar
• BrugtsJJYetginTHoeksSEThe benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBMJ2009338b237619567909
   PubMed Web of Science ®Google Scholar
• LindgrenPBuxtonMKahanTASCOT investigatorsCosteffectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA)Eur J Cardiovasc Prev Rehabil200512293615703503
   PubMed Web of Science ®Google Scholar
• ShepherdJEconomics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention StudyAm J Cardiol20018719B22B
   PubMed Web of Science ®Google Scholar
• MichosEDBlumenthalRSPrevalence of Low Low-Density Lipoprotein Cholesterol with elevated high sensitivity C-reactive protein in the USJ Am Coll Cardiol20095393193519281922
   PubMed Web of Science ®Google Scholar